Strain Data Sheet

RBRC11518

Strain Information

Image
BRC No.RBRC11518
TypeCRISPR/Cas9 (Transgene)Cartagena
SpeciesMus musculus
Strain nameC57BL/6-App<tm2(NL-F)Tcs> Psen1<em1(P117L)Tcs>
Former Common nameApp<NL-F>Psen1<P117L> mice
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain developmentDeposited by Takaomi C. Saido, RIKEN Center for Brain Science in 2022.
Strain descriptionApp knock-in mice having Swedish/Iberian (NL-F) mutations. This mutant also has a point mutation (P117L) in the Psen1 gene. Homozygous mutant mice are viable and fertile.
Colony maintenance
References
Single App knock-in mouse models of Alzheimer's disease.
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido T C
Nat. Neurosci., 17(5):661-663 (2014). 24728269

Introduction of pathogenic mutations into the mouse Psen1 gene by Base Editor and Target-AID.
Hiroki Sasaguri, Kenichi Nagata, Misaki Sekiguchi, Ryo Fujioka, Yukio Matsuba, Shoko Hashimoto, Kaori Sato, Deepika Kurup, Takanori Yokota, Takaomi C Saido
Nat. Commun., 9(1):2892 (2018). 30042426

A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid β peptide.
Kaori Sato, Naoto Watamura, Ryo Fujioka, Naomi Mihira, Misaki Sekiguchi, Kenichi Nagata, Toshio Ohshima, Takashi Saito, Takaomi C Saido, Hiroki Sasaguri
J. Biol. Chem., 297(3):101004 (2021). 34329683

Health Report

Examination Date / Room / Rack2024/11/25Room:4-BRack:HSentinel mouse program
2024/08/26Room:4-BRack:HSentinel mouse program
2024/05/27Room:4-BRack:HSentinel mouse program
2024/02/26Room:4-BRack:HSentinel mouse program
2023/11/27Room:4-BRack:HSentinel mouse program
2023/08/30Room:4-BRack:HAdditional tests
2023/08/28Room:4-BRack:HSentinel mouse program
2023/05/29Room:4-BRack:HSentinel mouse program

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Psen1
MGI:1202717		presenilin 112Psen1<em1(P117L)Tcs>
MGI:7382956		endonuclease-mediated mutation 1, Takaomi C Saido
  • acne inversa, familial, 3(MedGEN)

  • Alzheimer disease 3(MedGEN)

  • dilated cardiomyopathy 1U(MedGEN)
    • more 2 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • Pick disease(DisGeNET, MedGEN)
    • App
    MGI:88059    		amyloid beta precursor protein16App<tm2(NL-F)Tcs>
    MGI:5637816    		targeted mutation 2, Takaomi C. Saido
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
    • Frt yeast FRT (flippase recombination target) site16Frt
    loxP phage P1 loxP16loxP

    Phenotype

    Annotation by Mammalian phenotyhpe ontology
    Detailed phenotype data

    Ordering Information

    Donor DNAphage P1 loxP site, yeast FRT (flipase recombination target) site, mouse App (amyloid beta (A4) precursor protein) genomic DNA (mutant type)
    Research applicationCre/loxP system
    FLP/frt system
    Mouse Models for Human Disease
    Specific Term and ConditionsThe BIOLOGICAL RESOURCE is the property of the RIKEN (The Institute of Physical and Chemical Research). RECIPIENT agrees to acknowledge Hiroki SASAGURI, Takashi SAITO and Takaomi C. SAIDO in an acknowledgement section. RECIPIENT also agrees to cite Nature Neuroscience 17, 661-663 (2014), J. Biol. Chem., 297(3):101004 (2021) and Nature Communications 9, 2892 (2018) in all publications obtained using BIOLOGICAL RESOURCE. RECIPIENT agrees to acknowledge DEPOSITOR in all oral presentations and written publications as related to the BIOLOGICAL RESOURCE. RECIPIENT shall keep confidential any or all information marked CONFIDENTIAL that is received from DEPOSITOR and related to the BIOLOGICAL RESOURCE including oral discussions if they are reduced to writing within thirty (30) days and are marked "CONFIDENTIAL". For-profit organizations must contact the DEPOSITOR (takaomi.saido@riken.jp) for a licensing contract. If any invention is conceived and reduced to practice by RECIPIENT in the performance of the Research Plan involving the BIOLOGICAL RESOURCE during the term of this MTA, RECIPIENT agrees to promptly inform the invention to DEPOSITOR and the parties will consult each other to determine inventorship and ownership of the invention based on the respective parties contribution to the invention, before filing an application for a patent. In the case of a jointly owned application, the parties will separately enter into a joint application agreement including the sharing of ownership, patent costs and licensing income, as well as the responsible party for the application procedures etc.
    DepositorTakaomi C. Saido (RIKEN CBS)
    Strain Statusan icon for Live miceLive mice
    an icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityCryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Live mouse (1 to 3 months)
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: CRISPR/Cas9 genome edited bioresources (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data